Your AI-Trained Oncology Knowledge Connection!

Opinion

Video

CDK4/6 Inhibitors Plus Novel Agents for ER+/HER2–Advanced or mBC

Panelists discuss perceptions on the efficacy and safety data for proteolysis targeting chimeras (PROTACs) and the selective estrogen receptor modulator (SERM) lasofoxifene in the treatment of HR+/HER2– breast cancer.

Video content above is prompted by the following:

Dr. Bardia to Dr. Shatsky: What are your perceptions on PROTAC efficacy and safety data?

Dr. Bardia to Dr. Shatsky: What are your perceptions on efficacy and safety data on the SERM lasofoxifene?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Tanya Gupta, MD
March 21st 2025

Selection of Frontline CDK4/6 Inhibitors Hinges on Patient Health Status in HR+/HER2– Metastatic Breast Cancer

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Vepdegestrant boosts PFS in select ESR1-mutated breast cancer, maintenance OSE2101 combination provides survival benefit in PDAC, and more from OncLive.
March 15th 2025

The OncFive: Top Oncology Articles for the Week of 3/9

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Vepdegestrant in Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 11th 2025

Vepdegestrant Hits PFS End Point in ESR1-Mutated, ER+/HER2– Metastatic Breast Cancer

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 10th 2025

Alisertib Plus Endocrine Therapy Is Under Evaluation in HR+/HER2-Negative Metastatic Breast Cancer